Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 19, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical …